GLP-1 產能擴張速度(供給是否跟上需求)
僅有間接線索資料截至 2026-09-30
間接證據:本期營收變動 6.2%,毛利率變動 -1.9 個百分點。該結果只描述“產品放量質量”,不能單獨驗證當前研究變數,因此不輸出積極或負面結論。
產品放量質量:營收 6.2%;毛利率變動 -1.9 個百分點
繼續關注:同一產品的出貨、交付、產能或量產里程碑
暫未列出足以直接回答此問題的依據。
檢視依據與尚未確認的問題
僅憑公司整體收入或毛利率尚不能回答此問題。
間接線索 · 3 份檔案
客戶與供應鏈 · 10-Q 審閱文件原文 · 3 條摘錄
閱讀原文 ↗- issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
- litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
- We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
客戶與供應鏈 · 10-Q 審閱文件原文 · 4 條摘錄
閱讀原文 ↗- issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
- litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
- We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
- As of June 30, 2026, we have the right to receive up to $ 410 million in potential sales-based milestones related to the Jardiance product family in certain markets in 2026.
客戶與供應鏈 · 10-Q 審閱文件原文 · 1 條摘錄
閱讀原文 ↗- issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
背景資料 · 12 份檔案
10-Q(提交於 2026-10-29) · 13 條摘錄
閱讀原文 ↗- 2026 Q3:營收 24.40 十億美元,毛利率 83.88%,自由現金流 未披露。
- LLY 於 2026-10-29 提交 10-Q:截至 2026-09-30 的定期報告。
- This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
- the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
- Acquired in-process research and development 4,181 656 7,541 2,381
- Acquired in-process research and development 7,541 2,381
- We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss, for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis, in Europe.
- We have a license agreement with Chugai Pharmaceutical Co., Ltd. (Chugai), which provides us the worldwide development and commercialization rights to orforglipron, which is branded and trademarked as Foundayo.
- We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
- When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.
- The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.
- The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.
- Acquisition date June 25, 2026 June 24, 2026 March 4, 2026
10-Q(提交於 2026-08-05) · 12 條摘錄
閱讀原文 ↗- 2026 Q2:營收 22.97 十億美元,毛利率 85.78%,自由現金流 未披露。
- LLY 於 2026-08-05 提交 10-Q:截至 2026-06-30 的定期報告。
- This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
- the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
- Acquired in-process research and development 2,776 154 3,360 1,726
- Acquired in-process research and development 3,360 1,726
- We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss, for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis, in Europe.
- We have a license agreement with Chugai Pharmaceutical Co., Ltd (Chugai), which provides us the worldwide development and commercialization rights to orforglipron, which is branded and trademarked as Foundayo.
- We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
- When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.
- The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.
- The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.
SCHEDULE 13D 原始檔案 · 5 條摘錄
閱讀原文 ↗- LLY 於 2026-10-16 提交 SCHEDULE 13D:股東行動。
- If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
- The name, business address, present principal occupation or employment and citizenship of each director and executive officer (including a director and officer who may be a controlling person) of the Reporting Person is set forth on Schedule A.
- The funds used by the Reporting Person to acquire the Common Stock purchased in the IPO consisted of cash on hand.
- The Reporting Person acquired the securities reported herein for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis.
併購交易 · SCHEDULE 13D 審閱文件原文 · 4 條摘錄
閱讀原文 ↗- If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
- The name, business address, present principal occupation or employment and citizenship of each director and executive officer (including a director and officer who may be a controlling person) of the Reporting Person is set forth on Schedule A.
- The funds used by the Reporting Person to acquire the Promissory Note and the Common Stock purchased in the IPO consisted of cash on hand.
- The Reporting Person acquired the securities reported herein for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis.
訴訟進展 · 10-Q 審閱文件原文 · 13 條摘錄
閱讀原文 ↗- This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
- the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
- litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
- We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
- As of March 31, 2026, we have the right to receive up to $ 660 million in potential sales-based milestones related to the Jardiance product family in certain markets in 2026.
- We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss, for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis, in Europe.
- We have a license agreement with Chugai Pharmaceutical Co., Ltd (Chugai), which provides us the worldwide development and commercialization rights to orforglipron, which is branded and trademarked as Foundayo.
- We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
- When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.
- The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.
- The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.
- In March 2026, we acquired all shares of Ventyx Biosciences, Inc. (Ventyx) for a purchase price of $ 14.00 per share in cash (or an aggregate of $ 1.1 billion, net of cash acquired).
- Our access to information was limited prior to this acquisition.
訴訟進展 · 10-K 審閱文件原文 · 14 條摘錄
閱讀原文 ↗- This Annual Report on Form 10-K and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
- issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
- the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
- litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
- Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.
- We adapt our marketing methods and product emphasis in various countries to meet local customer needs and comply with local regulations.
- See, for examples, Item 1A, "Risk Factors—Risks Related to Our Operations—Failure, inadequacy, breach of, or unauthorized access to, our IT systems or those of our third-party service providers, unauthorized access to our confidential information, or violations of data protection laws, could result in material harm to our business and reputation" and "Risk Factors—Risks Related to Litigation and Government Regulation—Regulatory compliance problems could be damaging to the company."
- A specific use of a drug or biologic can receive "orphan" designation in the U.S. if it is intended to treat a disease or condition affecting fewer than 200,000 people in the U.S., or where it is not reasonably expected to recover development and marketing costs through U.S. sales.
- The length of market exclusivity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusivity and the inherent uncertainties regarding patent litigation.
- Some of our products are subject to significant license and collaboration agreements.
- For information on our license and collaboration agreements, see Item 8, "Financial Statements and Supplementary Data—Note 3: Collaborations and Other Arrangements."
- The patent litigation scheme under the BPCIA, and the BPCIA itself, is complex and continues to be interpreted and implemented by the FDA, as well as by courts.
- Courts have held that biosimilar applicants are not required to engage in the BPCIA patent litigation scheme and patent holders retain the right to bring suit under normal patent law procedures if a biosimilar applicant attempts to commercialize a product prior to patent expiration.
- For more information on patent challenges and litigation involving our intellectual property rights, see Item 1A, "Risk Factors—Risks Related to Our Intellectual Property—Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected" and Item 8, "Financial Statements and Supplementary Data—Note 16: Contingencies."
訴訟進展 · 10-Q 審閱文件原文 · 14 條摘錄
閱讀原文 ↗- This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
- issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
- the use of artificial intelligence or other emerging technologies in various facets of our operations, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
- litigation, investigations, or other similar proceedings involving past, current, or future products or activities;
- Acquired in-process research and development (Note 3) 655.7 2,826.4 2,381.2 3,091.2
- (1) As of September 30, 2025, there was $ 12.40 billion remaining under our $ 15.00 billion share repurchase program authorized in December 2024.
- Acquired in-process research and development 2,381.2 3,091.2
- We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
- We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
- When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.
- The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.
- The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.
- In July 2025, we acquired all shares of Verve Therapeutics, Inc. (Verve) for a purchase price of $ 10.50 per share in cash (or an aggregate of approximately $ 549.4 million, net of cash acquired), plus one non-tradeable contingent value right (CVR) per share that entitles the holder to receive up to an additional $ 3.00 per share (or an aggregate of up to approximately $ 300 million) payable, subject to certain terms and conditions, upon the achievement of a certain specified milestone.
- Our access to information was limited prior to this acquisition.
訴訟進展 · 10-Q 審閱文件原文 · 14 條摘錄
閱讀原文 ↗- This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
- issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
- the use of artificial intelligence or other emerging technologies in various facets of our operations, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
- litigation, investigations, or other similar proceedings involving past, current, or future products or activities;
- Acquired in-process research and development (Note 3) 153.8 154.3 1,725.5 264.8
- (1) As of June 30, 2025, there was $ 13.11 billion remaining under our $ 15.00 billion share repurchase program authorized in December 2024.
- Acquired in-process research and development 1,725.5 264.8
- We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
- We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
- When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.
- The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.
- The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.
- In May 2024, we acquired NexPharm Parent HoldCo, LLC and Isopro Holdings, LLC, which together own the assets of a manufacturing site in Wisconsin, for a purchase price of $ 924.7 million, net of cash acquired.
- The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
訴訟進展 · 10-Q 審閱文件原文 · 14 條摘錄
閱讀原文 ↗- This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
- issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
- the use of artificial intelligence or other emerging technologies in various facets of our operations, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
- litigation, investigations, or other similar proceedings involving past, current, or future products or activities;
- Acquired in-process research and development (Note 3) 1,571.7 110.5
- (1) As of March 31, 2025, there was $ 13.80 billion remaining under our $ 15.00 billion share repurchase program authorized in December 2024.
- Acquired in-process research and development 1,571.7 110.5
- We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
- We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
- Upon each asset acquisition, the cost allocated to acquired in-process research and development (IPR&D) was immediately expensed as acquired IPR&D if the compound had no alternative future use.
- Milestone payment obligations incurred prior to regulatory approval of the compound were expensed as acquired IPR&D when the event triggering an obligation to pay the milestone occurred.
- We recognized acquired IPR&D charges of $ 1.57 billion and $ 110.5 million for the three months ended March 31, 2025 and 2024, respectively.
- The acquired IPR&D charges for the three months ended March 31, 2025 were primarily related to the acquisition of Scorpion Therapeutics, Inc.'s (Scorpion's) PI3Kα inhibitor program STX-478, currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors.
- We recognized no other significant acquired IPR&D charges during the three months ended March 31, 2025 and 2024.
訴訟進展 · 10-K 審閱文件原文 · 14 條摘錄
閱讀原文 ↗- This Annual Report on Form 10-K and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
- issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
- the use of artificial intelligence or other emerging technologies in various facets of our operations may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
- litigation, investigations, or other similar proceedings involving past, current, or future products or activities;
- Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.
- We adapt our marketing methods and product emphasis in various countries to meet local customer needs and comply with local regulations.
- business and reputation" and "Risk Factors—Risks Related to Litigation and Government Regulation—Regulatory compliance problems could be damaging to the company."
- In recent periods, we have seen an increase in the production, marketing, and sale of counterfeit, misbranded, adulterated, and compounded incretins.
- A specific use of a drug or biologic can receive "orphan" designation in the U.S. if it is intended to treat a disease or condition affecting fewer than 200,000 people in the U.S., or where it is not reasonably expected to recover development and marketing costs through U.S. sales.
- The length of market exclusivity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusivity and the inherent uncertainties regarding patent litigation.
- Some of our products are subject to significant license and collaboration agreements.
- For information on our license and collaboration agreements, see Item 8, "Financial Statements and Supplementary Data—Note 4: Collaborations and Other Arrangements."
- The patent litigation scheme under the BPCIA, and the BPCIA itself, is complex and continues to be interpreted and implemented by the FDA, as well as by courts.
- Courts have held that biosimilar applicants are not required to engage in the BPCIA patent litigation scheme and patent holders retain the right to bring suit under normal patent law procedures if a biosimilar applicant attempts to commercialize a product prior to patent expiration.
